Evidence map›Paper›PMID 34870678›Full record

ArticleJAMA network open2021

Clinician Trends in Prescribing Direct Oral Anticoagulants for US Medicare Beneficiaries.

Kevin M Wheelock, Joseph S Ross, Karthik Murugiah, Zhenqiu Lin, Harlan M Krumholz, Rohan Khera

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 2 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.

  1. Guideline
  2. Effectiveness and Safety of Aspirin Versus Other Antithrombotics for VTE After Total Hip and Knee Arthroplasty in Real-World Setting.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kevin M WheelockDepartment of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
Joseph S RossCenter for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut.
Karthik MurugiahCenter for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut.
Zhenqiu LinCenter for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut.
Harlan M KrumholzCenter for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut.
Rohan KheraCenter for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut.
Yale New Haven Hospital · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Evaluating and Improving Utilization of Evidence-Based Medical Therapy in Patients with Heart Failure using Automated Tools in the Electronic Health RecordK23HL153775 · NHLBI · YALE UNIVERSITY · PI KHERA, ROHAN · 2021 to 2025
$918k
NCATS NIH HHS UL1 TR001863NHLBI NIH HHS K23 HL153775
6 · The paper itself

Abstract

Importance: Contemporary national clinical practice guidelines recommend direct-acting oral anticoagulants (DOACs) as the first-line anticoagulant strategy over warfarin for most indications, especially among older individuals with an elevated bleeding risk. Objective: To evaluate anticoagulant prescribing and DOAC uptake by US clinicians in the Medicare population. Design, Setting, and Participants: This retrospective cohort study included all US clinicians with more than 10 Medicare oral anticoagulant prescription claims, who were included in the national Medicare Provider Utilization and Payment Data (2013-2018). Data analyses were conducted between October 2020 and October 2021. Exposures: DOAC prescription in 2013. Main Outcomes and Measures: Clinicians were categorized based on 2013 prescribing as solely prescribing warfarin, DOAC, or both, and their temporal trajectories of proportionate DOAC use were examined. Results: The analysis included 325 666 unique clinicians with more than 10 oral anticoagulant prescriptions between 2013 and 2018 (26 620 [8.2%] cardiologists, 85 563 [26.3%] internal medicine physicians, 84 369 [25.9%] family medicine physicians, and 81 161 [24.9%] advanced practice clinicians, including nurse practitioners and physician assistants). In 2013, among 91 837 prescribers, 54 501 (59.3%) prescribed only warfarin, 1918 (2.1%) prescribed only a DOAC, and 35 418 (38.6%) prescribed both. During the study period, the number of clinicians prescribing DOACs increased, but 19% continued to prescribe only warfarin in 2018. While 359 cardiologists prescribing anticoagulants (1.6%) were warfarin-only prescribers, 10 414 (20.0%) and 6296 (12.6%) of family and internal medicine physicians also prescribed only warfarin, respectively. Clinicians prescribing only warfarin in 2013 had lower proportionate DOAC use throughout the study compared with 2013 DOAC prescribers, which represents a median (IQR) of 41.9% (20.3%-61.9%) of their anticoagulant prescriptions in 2018 vs 67.0% (49.9%-82.8%) for DOAC prescribers. Conclusions and Relevance: Despite the increase in DOAC use among Medicare beneficiaries, many clinicians in this study continued to use warfarin as their predominant or only anticoagulant instead of DOACs. There is a need to address barriers to the uptake of these medications to realize their potential benefits for patients.

Indexed as

MedicareAdministration, OralAtrial FibrillationFactor Xa InhibitorsHumansPractice Patterns, Physicians'Retrospective StudiesTime FactorsUnited StatesWarfarinFactor Xa InhibitorsWarfarin

Identifiers

PMID34870678
PMCPMC8649845
OpenAlexW4200102179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.